Last updated: February 13, 2026
Product Overview
NDC 00075-0622 corresponds to the drug Ribavirin Injection, a broad-spectrum antiviral used primarily in combination therapies for hepatitis C virus (HCV) and certain viral hemorrhagic illnesses. It is marketed by Pfizer, with specific formulations tailored for hospital and clinical use.
Market Size and Key Drivers
- Market Segment: The global antiviral drug market, specifically the hepatitis C treatment segment, has seen rapid growth due to the high prevalence of HCV. Ribavirin's role is predominantly as an auxiliary drug alongside modern direct-acting antivirals (DAAs).
- Prevalence: According to the World Health Organization (WHO), approximately 58 million people globally are infected with HCV. The U.S. accounts for roughly 2.4 million cases.
- Current Treatment Trends: Shift toward DAA-based regimens has led to declining use of Ribavirin; however, it remains essential in certain treatment protocols, especially where resistance to newer agents occurs or in resource-limited settings.
Market Trends
- Use of Ribavirin has dropped in developed countries but persists in developing regions due to cost and availability.
- The demand in hospital settings maintains a baseline, although growth is stagnant.
- The increased focus on pediatric and special populations could influence future demand.
Pricing Analysis
- Current Average Wholesale Price (AWP): Approximately $200 per 1,000 mg vial (varies by supplier and region).
- Historical Pricing Trends: Prices peaked around 2010 at approximately $400 per vial but have since declined due to generic entry and market competition.
- Pricing Differentials: In hospital settings, the acquisition cost can be 20-50% lower due to bulk purchasing and negotiated discounts.
Price Projections (Next 5 Years)
| Year |
Expected Price Range per 1,000 mg vial |
Factors Influencing Prices |
| 2023 |
$150 - $200 |
Stabilized market, limited new competition |
| 2024 |
$140 - $190 |
Price competition persists, pressure from generics |
| 2025 |
$130 - $180 |
Increased generic penetration, biosimilars emerging |
| 2026 |
$120 - $170 |
Market saturation, potential development of biosimilars |
| 2027 |
$110 - $160 |
Further commoditization, supply chain efficiencies |
Competitive Landscape
- Generics: Several manufacturers produce generic Ribavirin, causing downward pressure on prices.
- Biosimilars: No biosimilar versions exist for Ribavirin, but small-molecule competition drives prices lower.
- Patent Status: Pfizer's patent for Ribavirin has expired in major markets, facilitating generic entry.
Regulatory and Policy Impact
- Regulatory bodies like the FDA and EMA have approved generic versions, further increasing market competition.
- Pricing policies in different countries influence the actual transaction prices, with price caps in many developed countries.
Supply Chain Dynamics
- Reliance on global manufacturing hubs in India and China impacts availability and pricing.
- Supply shortages have historically triggered price spikes, but current supply chains maintain stability.
Key Market Risks
- Declining demand due to newer treatments diminishes revenue.
- Cost pressure from generics and biosimilars impacts profitability.
- Regulatory changes, particularly price controls, may further reduce margins.
Key Takeaways
- The global Ribavirin injection market experiences a decline driven by newer antivirals, with residual demand in niche applications.
- Prices have stabilized at historically lower levels compared to peak periods, with projections indicating gradual decline over the next five years.
- Market dynamics are heavily influenced by generic competition, with biosimilars not yet emerging for Ribavirin.
- Pricing policies and manufacturing supply chains significantly impact actual procurement costs worldwide.
- Investment or strategic decisions should consider the shrinking market size and ongoing price compression.
FAQs
1. Is NDC 00075-0622 still a commercially viable product?
Use is limited to specific clinical scenarios, resulting in a niche market with reduced revenue potential.
2. What are the main competitors to Ribavirin injection?
Direct competitors include newer oral antiviral agents with superior efficacy and fewer side effects, leading to decreasing reliance on injectable Ribavirin.
3. How does patent status affect this drug’s pricing?
Since patent expiration in key markets, generic versions have entered, pressuring prices downward.
4. Are biosimilars a threat to Ribavirin?
No; biosimilars are not applicable to small-molecule drugs like Ribavirin, but generic competition significantly impacts pricing.
5. What regulatory factors could influence future prices?
Government policies on drug pricing, reimbursement schemes, and safety regulations may influence procurement costs and profitability.
Citations
- WHO. "Hepatitis C Fact Sheet." 2022.
- IQVIA. "Global Virology Market Report," 2022.
- U.S. FDA. "Approved Drugs: Ribavirin," 2023.
- Pharma intelligence. "Generic Drug Price Trends," 2022.
- MarketWatch. "Antiviral Drug Market Outlook," 2023.
